Navigation Links
Prometheus Research Signs 3-Year Contract With Simons Foundation to Expand HTSQL Informatics System for Autism Research

SFARI Base to Usher in 'New Paradigm of Research Collaboration'

NEW HAVEN, Conn., June 2 /PRNewswire/ -- Prometheus Research has signed a three year contract with the New York-based Simons Foundation to expand their development partnership on SFARI Base, the HTSQL-based informatics platform that helps researchers collaborate on understanding the causes of autism. The collaboration is part of the Simons Foundation Autism Research Initiative (SFARI).

Prometheus, a database management software company headquartered here, created the groundbreaking HTSQL platform, which allows for real-time access and configuration of databases via the web. Their flagship product for the biomedical research market, RexDB(R), formed the basis for SFARI Base, and is already used by over a dozen leading research universities, such as Harvard, Yale, Columbia, and the University of California - Los Angeles.

"Prometheus Research and its HTSQL web-based database software are enabling researchers to usher in a new paradigm of research collaboration with SFARI Base," said Stephen B. Johnson PhD, Associate Professor, Biomedical Informatics, Columbia University, working with the Simons Foundation. "This web-based tool offers researchers unprecedented access to DNA specimens on affected families, combined with high quality phenotype data," Johnson said.

The SFARI mission is to improve the diagnosis, treatment, and prevention of autism and related developmental disorders. The SFARI database, known as SFARI Base, is a new resource for autism research that provides the scientific community access to genetic and phenotypic information on 2000 families.

"Researchers need flexible, adaptive, and secure informatics systems that empower them to uncover critical data easily, from wherever they are, over the web," said Leon Rozenblit, president, Prometheus Research. "HTSQL enables us to quickly and efficiently develop customized solutions that increase organizational intelligence, save time, and save money by making data a shared resource that collaborators can access as needed."

About Prometheus Research

Prometheus Research, New Haven, Conn., is a software development and professional services company innovating web-based tools to empower knowledge workers by making existing databases easily available on the web. Prometheus HTSQL quickly translates the language of the web (HTTP) into the language of databases (SQL), allowing businesses and organizations to securely increase their intelligence through dynamic, real-time, web-based database management. Prometheus RexDB(R), a biomedical application, is used by world-renowned researchers and simplifies development of custom informatics systems for secure access to rich scientific data. For more information, go to

SOURCE Prometheus Research
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Prometheus Licenses COLAL-PRED(R) From Alizyme
2. Prometheus Strengthens Intellectual Property Portfolio with Newly Issued Patents for Thiopurine Metabolite Testing
3. Prometheus Receives New York State Approval for PROMETHEUS(R) IBS Diagnostic, First Blood Test for Irritable Bowel Syndrome
4. Research Triangle Area Health Care Collaborative Launches Bridges to Excellence(R) Initiative to Improve Quality and Lower Costs
5. The Multiple Myeloma Research Consortium (MMRC) and Proteolix Initiate Phase 2 Clinical Trial Investigating Carfilzomib for the Treatment of Multiple Myeloma
6. BioMarin Licenses Technology From Leading Cystic Fibrosis Research Laboratory at the University of California, San Francisco
7. IDM Pharma Names Dr. Jeffrey W. Sherman Chief Medical Officer and Senior Vice President of Research and Development
8. Dawson James Securities Initiates Research Coverage on CryoCor, Inc. (Nasdaq: CRYO) with a Strong Buy Rating and $6.00 Target Price
9. eResearchTechnology to Present at the Thomas Weisel Healthcare Conference 2007 on September 5th
10. The Debiopharm Life Sciences Award Goes to Dr Nusser for his Outstanding Research in Neuroscience
11. Study Published in Clinical Cancer Research Confirms Potential Of Peregrines Bavituximab Combined With Radiation In Lung Cancer
Post Your Comments:
(Date:6/23/2016)... ... June 23, 2016 , ... Charm Sciences, ... microbial test has received AOAC Research Institute approval 061601. , “This is another ... year,” stated Bob Salter, Vice President of Regulatory and Industrial Affairs. “The Peel ...
(Date:6/23/2016)... June 23, 2016   EpiBiome , a precision ... million in debt financing from Silicon Valley Bank (SVB). ... and to advance its drug development efforts, as well ... "SVB has been an incredible strategic partner ... a traditional bank would provide," said Dr. Aeron ...
(Date:6/23/2016)... ... June 23, 2016 , ... In a new case report published today in ... patient who developed lymphedema after being treated for breast cancer benefitted from an injection ... for dealing with this debilitating, frequent side effect of cancer treatment. , ...
(Date:6/23/2016)... 2016 Andrew D ... Published recently in ... from touchONCOLOGY, Andrew D Zelenetz , discusses ... care is placing an increasing burden on healthcare ... therapies. With the patents on many biologics expiring, ...
Breaking Biology Technology:
(Date:6/2/2016)... June 2, 2016   The Weather Company , an ... Ads, an industry-first capability in which consumers will be able ... to ask questions via voice or text and receive relevant ... Marketers have long sought an advertising solution ... can be personal, relevant and valuable; and can scale across ...
(Date:5/16/2016)...   EyeLock LLC , a market leader of ... an IoT Center of Excellence in Austin, ... of embedded iris biometric applications. EyeLock,s iris ... security with unmatched biometric accuracy, making it the most ... EyeLock,s platform uses video technology to deliver a fast ...
(Date:4/28/2016)... Sweden , April 28, 2016 First ... M (139.9), up 966% compared with the first quarter of 2015 ... profit totaled SEK 589.1 M (loss: 18.8) and the operating margin ... 7.12 (loss: 0.32) Cash flow from operations was SEK ... The 2016 revenue guidance is unchanged, SEK 7,000-8,500 M. ...
Breaking Biology News(10 mins):